These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein-Barr Virus Reactivation. Kumata K; Nagata K; Matsushita M; Kuwamoto S; Kato M; Murakami I; Fukata S; Hayashi K Viral Immunol; 2016 Oct; 29(8):459-463. PubMed ID: 27529807 [TBL] [Abstract][Full Text] [Related]
9. The influence of Epstein-Barr virus reactivation in patients with Graves' disease. Nagata K; Fukata S; Kanai K; Satoh Y; Segawa T; Kuwamoto S; Sugihara H; Kato M; Murakami I; Hayashi K; Sairenji T Viral Immunol; 2011 Apr; 24(2):143-9. PubMed ID: 21449724 [TBL] [Abstract][Full Text] [Related]
10. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule. Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592 [TBL] [Abstract][Full Text] [Related]
12. Presence of Epstein-Barr virus-infected B lymphocytes with thyrotropin receptor antibodies on their surface in Graves' disease patients and in healthy individuals. Nagata K; Higaki K; Nakayama Y; Miyauchi H; Kiritani Y; Kanai K; Matsushita M; Iwasaki T; Sugihara H; Kuwamoto S; Kato M; Murakami I; Nanba E; Kimura H; Hayashi K Autoimmunity; 2014 May; 47(3):193-200. PubMed ID: 24467196 [TBL] [Abstract][Full Text] [Related]
13. Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture. Tanner JE; Hu J; Alfieri C Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29642526 [TBL] [Abstract][Full Text] [Related]
14. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells. Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675 [TBL] [Abstract][Full Text] [Related]
15. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC. Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258 [TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116 [TBL] [Abstract][Full Text] [Related]
17. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis. Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645 [TBL] [Abstract][Full Text] [Related]
18. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087 [TBL] [Abstract][Full Text] [Related]
19. Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo. Servat E; Ro BW; Cayatte C; Gemmell L; Barton C; Rao E; Lin R; Zuo F; Woo JC; Hayes GM Vaccine; 2015 Nov; 33(48):6771-7. PubMed ID: 26485517 [TBL] [Abstract][Full Text] [Related]
20. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]